Next Article in Journal / Special Issue
Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection
Previous Article in Journal / Special Issue
The Antimicrobial Stewardship Approach to Combating Clostridium Difficile
Article Menu

Export Article

Open AccessReview
Antibiotics 2015, 4(2), 216-229;

Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection

Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan 70043, Taiwan
Department of Internal Medicine, National Cheng Kung University Hospital, No. 138, Sheng Li Road, Tainan 70403, Taiwan
Graduate Institute of Clinical Medicine, National Health Research Institutes, Tainan 70403, Taiwan
Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Medical College, Tainan 70102, Taiwan
Department of Internal Medicine, E-da Hospital, Kaohsiung 82445, Taiwan
Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan 70102, Taiwan
Department of Medicine, National Cheng Kung University, Medical College, Tainan 70102, Taiwan
Author to whom correspondence should be addressed.
Academic Editor: Yung-Fu Chang
Received: 8 March 2015 / Revised: 25 April 2015 / Accepted: 15 June 2015 / Published: 19 June 2015
(This article belongs to the Special Issue Clostridium difficile Infection)
Full-Text   |   PDF [828 KB, uploaded 19 June 2015]


Clostridium difficile infection (CDI) is known to be associated with prior exposure to many classes of antibiotics. Standard therapy for CDI (i.e., metronidazole and vancomycin) is associated with high recurrence rates. Although tetracycline derivatives such as tetracycline, doxycycline or tigecycline are not the standard therapeutic choices for CDI, they may serve as an alternative or a component of combination therapy. Previous tetracycline or doxycycline usage had been shown to have less association with CDI development. Tigecycline, a broad-spectrum glycylcycline with potency against many gram-positive or gram-negative pathogens, had been successfully used to treat severe or refractory CDI. The in vitro susceptibility of C. difficile clinical isolates to tigecycline in many studies showed low minimal inhibitory concentrations. Tigecycline can suppress in vitro toxin production in both historical and hypervirulent C. difficile strains and reduce spore production in a dose-dependent manner. Tetracycline compounds such as doxycycline, minocycline, and tigecycline possess anti-inflammatory properties that are independent of their antibiotic activity and may contribute to their therapeutic effect for CDI. Although clinical data are limited, doxycycline is less likely to induce CDI, and tigecycline can be considered one of the therapeutic choices for severe or refractory CDI. View Full-Text
Keywords: Clostridium difficile; doxycycline; tigecycline Clostridium difficile; doxycycline; tigecycline
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hung, Y.-P.; Lee, J.-C.; Lin, H.-J.; Liu, H.-C.; Wu, Y.-H.; Tsai, P.-J.; Ko, W.-C. Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection. Antibiotics 2015, 4, 216-229.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top